logo

Amylyx Pharmaceuticals, Inc (AMLX)



Trade AMLX now with
  Date
  Headline
9/29/2022 10:58:53 PM FDA Approves Amylyx's ALS Drug
8/3/2022 9:10:36 AM Amylyx Pharma : FDA Panel To Reconvene To Review NDA For AMX0035 For Treatment Of ALS On September 7
7/5/2022 9:05:36 AM Amylyx :FDA Plans To Reconvene Advisory Committee To Review AMX0035 NDA For Treatment Of ALS On September 7
6/3/2022 7:02:33 AM Amylyx Pharma Gets Notification Of PDUFA Date Extension For AMX0035 For Treatment Of ALS
5/5/2022 10:00:12 AM Amylyx Reports Publication Of Trial Analyses Demonstrating Survival Benefit With AMX0035 In People With ALS
4/2/2022 10:06:59 AM Amylyx Pharmaceuticals Announces Oral Presentation Of Safety And Tolerability Data On AMX0035 From Clinical Trials
3/28/2022 10:52:26 AM Amylyx : FDA's Panel Meeting Scheduled On March 30 To Review NDA Of AMX0035 For Amyotrophic Lateral Sclerosis Treatment
2/23/2022 8:21:36 AM Amylyx Pharma Appoints Gina Mazzariello As Chief Legal Officer And General Counsel